West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.
Highlights
WST's EPS is up by 25% year-on-year and by 10% since the previous quarter
The net income has grown by 25% YoY and by 10% from the previous quarter
The stock's price to earnings (P/E) is 57% more than its 5-year quarterly average of 45.1 and 46% more than its last 4 quarters average of 48.3
WST's debt is up by 20% year-on-year
Key stats
What are the main financial stats of WST
Market
Shares outstanding
73.84M
Market cap
$20.22B
Enterprise value
$20.11B
Valuations
Price to earnings (P/E)
70.59
Price to book (P/B)
12.55
Price to sales (P/S)
10.39
EV/EBIT
57.07
EV/EBITDA
44.08
EV/Sales
10.33
Earnings
Revenue
$1.95B
EBIT
$352.3M
EBITDA
$456.1M
Free cash flow
$281.2M
Per share
EPS
$3.88
Free cash flow per share
$3.81
Book value per share
$21.82
Revenue per share
$26.36
TBVPS
$30.54
Balance sheet
Total assets
$2.39B
Total liabilities
$786M
Debt
$326.9M
Equity
$1.61B
Working capital
$735.4M
Liquidity
Debt to equity
0.2
Current ratio
2.96
Quick ratio
2.1
Net debt/EBITDA
-0.26
Margins
EBITDA margin
23.4%
Gross margin
34.1%
Net margin
14.7%
Operating margin
17%
Efficiency
Return on assets
12.5%
Return on equity
18.6%
Return on invested capital
20.6%
Return on capital employed
17.5%
Return on sales
18.1%
Dividend
Dividend yield
0.23%
DPS
$0.63
Payout ratio
16.2%
WST stock price
How has the West Pharmaceutical Services stock price performed over time
Financial performance
How have West Pharmaceutical Services's revenue and profit performed over time
Revenue
$1.95B
Gross profit
$663.1M
Operating income
$331M
Net income
$285.7M
Gross margin
34.1%
Net margin
14.7%
The net income has grown by 25% YoY and by 10% from the previous quarter
WST's operating income is up by 19% YoY and by 8% from the previous quarter
The gross profit has grown by 16% YoY and by 6% from the previous quarter
WST's net margin is up by 14% year-on-year and by 7% since the previous quarter
Valuation
What is West Pharmaceutical Services stock price valuation
P/E
70.59
P/B
12.55
P/S
10.39
EV/EBIT
57.07
EV/EBITDA
44.08
EV/Sales
10.33
The stock's price to earnings (P/E) is 57% more than its 5-year quarterly average of 45.1 and 46% more than its last 4 quarters average of 48.3
WST's EPS is up by 25% year-on-year and by 10% since the previous quarter
The price to book (P/B) is 113% higher than the 5-year quarterly average of 5.9 and 57% higher than the last 4 quarters average of 8.0
WST's equity is up by 11% year-on-year and by 8% since the previous quarter
The P/S is 126% above the 5-year quarterly average of 4.6 and 57% above the last 4 quarters average of 6.6
West Pharmaceutical Services's revenue has increased by 10% YoY and by 3% from the previous quarter
Efficiency
How efficient is West Pharmaceutical Services business performance
West Pharmaceutical Services's ROE has increased by 13% YoY and by 7% from the previous quarter
The company's return on assets rose by 11% YoY and by 7% QoQ
WST's return on sales is up by 10% year-on-year and by 4.6% since the previous quarter
WST's return on invested capital is up by 7% year-on-year and by 6% since the previous quarter
Dividends
What is WST's dividend history
DPS
$0.63
Dividend yield
0.23%
Payout ratio
16.2%
Recent dividends
Financial health
How did West Pharmaceutical Services financials performed over time
The total liabilities has increased by 16% year-on-year and by 3.9% since the previous quarter
WST's total assets is up by 13% year-on-year and by 7% since the previous quarter
WST's debt is 80% smaller than its equity
WST's equity is up by 11% year-on-year and by 8% since the previous quarter
The debt to equity has contracted by 9% from the previous quarter but it has grown by 5% YoY
All financial data is based on trailing twelve months (TTM) periods - updated
quarterly, unless otherwise specified.